Research programme: cancer therapeutics - The Institute for Research in Immunology and Cancer - Commercialisation of Research/University of Montreal
Latest Information Update: 31 Mar 2023
At a glance
- Originator Institute for Research in Immunology and Cancer - Commercialization of Research; University of Montreal
- Developer Institute for Research in Immunology and Cancer - Commercialization of Research; Ipsen; University of Montreal
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer